In Depth 17 Jul 2025 New horizons in sickle cell disease treatment: Promising therapies on the way …particular revolutionizing the field. Table of contents The success of gene therapies for sickle cell disease November 16, 2023, marked a historic day for biotech: the U.K. Medicines and Healthcare… July 17, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2018 Fish Oils Finally Reel in Positive Results for Cardiovascular Disease Purified fish oil can reduce patients’ risks for adverse cardiovascular events by 25%, according to US-Irish Biotech Amarin’s Phase III trial results. The treatment, called Vascepa, significantly reduced the risk… September 26, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? …Wall Street. “I predict acquirers will be more likely to pay handsomely for approved or near-approval assets than hunt for risky bargains among the pre-phase 3 biotechs. Biotechs with the… January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment …participate in daily activities. In this article, we take a look at the events surrounding the historical approvals of the first two geographic atrophy treatments, and the ensuing rivalry between… November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Apr 2024 8 of the most expensive drugs in biopharma: Unraveling the costliest medications …expensive drugs, Hemgenix, developed by Amsterdam-based biotech uniQure in partnership with global biopharma CSL Behring, is a one-time gene therapy for adults with hemophilia B. The condition is a rare,… April 25, 2024 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it’s Too Late GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of… November 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Positive results from Milestone Pharmaceuticals’ phase 3 PSVT trial …RAPID trial continue to support the potential self-use of etripamil, with findings consistent with those observed in prior trials. The most common randomized treatment emergent adverse events (RTEAEs), adverse events… October 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Viridian reports positive news from ongoing trial for patients with Thyroid Eye Disease …20mg/kg of VRDN-001, no adverse events of hyperglycemia, muscle spasm, hearing impairment, infusion reactions, or any serious adverse events were reported as of the cutoff date of August 9, 2022…. August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Stramsen Biotech to look at 11 plant-based drug candidates Houston-based biotechnology firm Stramsen Biotech Inc. has announced 11 drug candidates for clinical development. Kefas Mugittu, co-CEO, made the announcement of the plant-based medical candidates. The company said the drugs… June 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Intracellular “smoke detector” discovery has skin disease therapy implications …cells. Fire alarm prevents long-lasting smoldering fire “This process is hugely important,” said Latz, who is also the spokesperson for the Cluster of Excellence ImmunoSensation2 and a member of the… March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the… June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 24 Mar 2021 How to Negotiate a Successful Research Collaboration Agreement Negotiating the terms of a research collaboration can be a minefield. Life sciences attorney Lori Waldron shares her extensive experience helping biotech and pharma companies negotiate agreements. Amid a dramatic… March 24, 2021 - 9 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email